![[U.S. Food and
Drug Administration]](https://webarchive.library.unt.edu/eot2008/20081006134529im_/http://www.fda.gov/icon/header.gif)
IMPORTANT PRESCRIBING NOTICE
FDA and USP have recently received reports noting confusion between Soriatane (acitretin)
Capsules and Loxitane (loxapine succinate) Capsules. Soriatane is a retinoid
that is
indicated for severe psoriasis. Because of its teratogenic potential, Soriatane should be
prescribed only by physicians who have special competence in the diagnosis and treatment of
severe psoriasis, are experienced in the use of systemic retinoids, and understand the risk
of teratogenicity. Loxitane is indicated for the management of the manifestations of psychotic
disorders. It has been available for a number of years and is currently also available
generically. The confusion occurs because, when written, a cursive capital "S" and "L" and
small "ri" and "xi" may look similar. This, coupled with the two products being available
in the same two strengths (10 and 25 mg) and dosage form (capsule), has created the possibility
for a serious dispensing error.
###
Return to Summary
![[FDA Home Page]](https://webarchive.library.unt.edu/eot2008/20081006134529im_/http://www.fda.gov/icon/iconhome.gif)